There are 411 papers on HDL-C in aging research: 84 trials and 239 observational studies in people, 16 in animals, 67 reviews.
411 papers study it1,133 more mention it148 findings
171 new papers in 30 daysSee all 1,544 papers on HDL-C
At a glance
Extremely low HDL-C is associated with higher mortality than markedly low levels in a human study. Human cohorts link higher HDL-C with lower coronary artery disease risk in men but higher fracture risk, while cognitive associations include an inverted U-shaped relationship in women. Trials report HDL-C increases with exercise and obicetrapib, but no clear effect with time-restricted feeding.
148 findings in 115 papers from 1999 to 2026, 28 of them since April 2026
“lower posttreatment HDL-C (β = -0.121; P = .004)”
- Human trial84
- Humans239
- Animals16
- In silico3
Interventions
43Obicetrapib
upin humans4+125%
4 studies
Obicetrapib
upin humans4+125%
Obicetrapib increases HDL-C in humans.
“Obicetrapib also showed substantial improvements in HDL-C and ApoB.”
Human trial
Endocrinology, diabetes & metabolism
Obicetrapib increases HDL-C in humans (MD +147.98).
“HDL cholesterol [MD, +147.98 (95% CI, 129.23-166.54), P < 0.001]”
Human trialn = 3,512
Cardiology in review
Obicetrapib increases HDL-C in humans (atherosclerosis cardiovascular disease) (+125%).
“Obicetrapib significantly lowered LDL‐C by 33% and increased HDL‐C by 125% relative to placebo.”
Human trialatherosclerosis cardiovascular disease12 monthsn = 1,727
AAIC 2025 abstract
Obicetrapib increases HDL-C in humans (on background statin therapy) (MD 156.21%; 95% CI 146.40% to 166.02%).
“HDL-C levels in the obicetrapib group were significantly higher (MD: 156.21%; 95% CI: 146.40% to 166.02%; p<0.00001)”
Human trialon background statin therapy10 mg
Evaluating Lipid-Lowering Efficacy Of Obicetrapib: An Updated Meta-Analysis of Clinical Trials
AHA Scientific Sessions 2025 abstract
Exercise
upin humans3
3 studies
Exercise
upin humans3
Exercise increases HDL-C in obese T2DM patients (MD = 0.12, 95% CI [0.05, 0.18]).
“HDL-C increased markedly (MD = 0.12, 95% CI [0.05, 0.18]”
Reviewin obese T2DM patients
Frontiers in immunology
Exercise increases HDL-C in humans (individuals with overweight or obesity) (Hedges' g = 0.51).
“moderate improvements in triglycerides (Hedges' g = -0.55), total cholesterol (Hedges' g = -0.23), and high-density lipoprotein cholesterol (HDL-C; Hedges' g = 0.51)”
Reviewindividuals with overweight or obesity
Biology of sport
Exercise increases HDL-C in humans.
“exercise increases HDL-cholesterol and reduces the triglyceride levels.”
Review
The role of cardiorespiratory fitness on plasma lipid levels
Expert review of cardiovascular therapy
Folic acid
upin humans1
1 study
Folic acid
upin humans1
Folic acid increases HDL-C in humans with resistance training (+0.21 ± 0.24 mmol/L vs -0.01 ± 0.12 mmol/L).
“The overall group effect was significant for HDL-C only (F = 3.43, P = 0.027).”
Human trialwith resistance training9 weeksmalesn = 40
Journal of the International Society of Sports Nutrition
Folic acid increases HDL-C in humans (combined with resistance training) (+0.21 ± 0.24 mmol/L).
“HDL-C increased more in the RF (+0.21 ± 0.24 mmol/L) than in the control (-0.01 ± 0.12 mmol/L; P < 0.01) and FA (+0.02 ± 0.16 mmol/L; P < 0.05).”
Human trialcombined with resistance training0.4 mg daily8 weeksmalesn = 40
Journal of the International Society of Sports Nutrition
Physical activity promotion program
upin humans1
1 study
Physical activity promotion program
upin humans1
Physical activity promotion program increases HDL-C in humans.
“For the 1st vs. 3rd pairwise comparison, significant differences were demonstrated in WHtR, HDL-C, cognitive function for attention and executive function (i.e., SCWT), and MVPA ≥ 150 min/wk, and sitting time.”
Human trial6 monthsn = 99
BMC public health
Physical activity promotion program increases HDL-C in humans (+2.84 mg/dL (95% CI: +0.82 to + 4.87)).
“HDL-C levels increased significantly by + 2.84 mg/dL (95% CI: +0.82 to + 4.87) at six months compared with baseline.”
Human trial6 monthsn = 87
BMC public health
Time-restricted feeding
no changein humans1upin humans1
1 study
Time-restricted feeding
no changein humans1upin humans1
Time-restricted feeding showed no clear effect on HDL-C in humans.
“Repeated measures ANOVA revealed no significant group-by-time interactions for both TC, TG, HDL-C and LDL-C.”
Human trialsix weeksn = 17
Journal of the International Society of Sports Nutrition
Time-restricted feeding increases HDL-C in humans.
“HDL-C levels significantly increased in the TRE group (p < 0.05) following the 6-week intervention”
Human trial6 weeksfemalesn = 10
Journal of the International Society of Sports Nutrition
Walking
upin humans1
1 study
Walking
upin humans1
Walking increases HDL-C in humans.
“As shown in Table and Fig., there were significant interactions between systolic pressure (P = 0.036), diastolic pressure (P = 0.036), HDL-C (P < 0.001), LDL-C (P < 0.001), and HbA1c (P = 0.001).”
Human trial24-week exercise programme and the 12-week retention periodfemalesn = 168
BMC geriatrics
Walking increases HDL-C in humans (P < 0.001).
“All walking conditions improved high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, step length, maximum oxygen consumption (VO2max), and oxidative capacity at anaerobic threshold (all P < 0.001)”
Human trial24 weeksfemalesn = 78
BMC geriatrics
Dehydroepiandrosterone
no changein humans1downin humans1
1 study
Dehydroepiandrosterone
no changein humans1downin humans1
Dehydroepiandrosterone showed no clear effect on HDL-C in humans (WMD 0.13 mg/dl, 95% CI: -1.4 to 1.7).
“not in males (WMD: 0.13 mg/dl, 95% CI: -1.4 to 1.7)”
Reviewmales
Nutrition, metabolism, and cardiovascular diseases : NMCD
Dehydroepiandrosterone decreases HDL-C in humans (WMD -5.1 mg/dl, 95% CI: -7.2 to -3).
“a significant reduction in HDL-C values was observed in studies comprising women (WMD: -5.1 mg/dl, 95% CI: -7.2 to -3)”
Reviewfemales
Nutrition, metabolism, and cardiovascular diseases : NMCD
Aerobic exercise
upin mice1
1 study
Aerobic exercise
upin mice1
Aerobic exercise increases HDL-C in mice (Compared with age-matched sedentary mice).
“HDL-C concentrations were significantly increased in the 36E1 group compared with the 36C group”
AnimalsCompared with age-matched sedentary micemoderate-intensity continuous aerobic exerciseserum3 times/week, 50 min/session6–36, 6–60, or 6–72 weeks of age
Chinese Journal of Gerontology
Cetp inhibitors
upin reviews1
1 study
Cetp inhibitors
upin reviews1
Cetp inhibitors increase HDL-C.
“Inhibition of CETP can increase high-density lipoprotein cholesterol (HDL-C) while reducing low-density lipoprotein cholesterol (LDL-C).”
Review
Progress on cholesteryl ester transfer protein-related genes and CETP inhibitor therapy
Yi chuan = Hereditas
Vegetarian diet
downin humans1
1 study
Vegetarian diet
downin humans1
Vegetarian diet is linked with lower HDL-C in humans (β = -3.4040, p < 0.0001).
“However, a vegetarian diet was associated with lower HDL-C (β = -3.4040, p < 0.0001).”
Humans>6 monthsn = 9,263
Frontiers in nutrition
Herbal supplements
downin humans1
1 study
Herbal supplements
downin humans1
Herbal supplements prevent HDL-C in humans (pesco-vegetarian diet).
“our study suggests that ginger and curcumin supplements may have blunted the decrease in HDL-C levels associated with vegetarian diets.”
Human trialpesco-vegetarian dietblood1 or 2 doses (500 mg)1 week
Nutrition and health
Pesco-vegetarian diet
downin humans1
1 study
Pesco-vegetarian diet
downin humans1
Pesco-vegetarian diet decreases HDL-C in humans (without ginger and curcumin supplementation).
“a significant decrease in blood high-density lipoprotein cholesterol (HDL-C) levels was observed in the 0 dose group but not in 1 or 2 dose groups.”
Human trialwithout ginger and curcumin supplementationblood0 dose1 week
Nutrition and health
Rosuvastatin + ezetimibe
upin humans1
1 study
Rosuvastatin + ezetimibe
upin humans1
Rosuvastatin + ezetimibe increases HDL-C in humans (elderly patients with atherosclerosis) (+18.4%, p<0.01).
“an 18,4% increase in HDL-C (p<0,01)”
Human trialelderly patients with atherosclerosisrosuvastatin 20 mg + ezetimibe 10 mg/day vs rosuvastatin 20 mg/day6 monthsn = 739
Russian Journal of Cardiology
Movie-theater-style meal
downin humans1
1 study
Movie-theater-style meal
downin humans1
Movie-theater-style meal decreases HDL-C in humans.
“while HDL-C decreased (ptime's ≤ 0.05)”
Human trialn = 10
The "Movie Theater" Study: Acute Cardiometabolic Effects of a Cinema-Style Meal
Metabolites
Diet
upin humans1+11%
1 study
Diet
upin humans1+11%
Diet increases HDL-C in humans (hypercholesterolemia) (+11%).
“Both groups exhibited a significant increase in HDL-C (+11%) and folic acid (+64%), along with a 35% reduction in LDH.”
Human trialhypercholesterolemia6 monthsn = 81
Nutrition, metabolism, and cardiovascular diseases : NMCD
All 43Fewer
Effects
10Cardiovascular disease
mediatesin humans2
2 studies
Cardiovascular disease
mediatesin humans2
HDL-C is linked with cardiovascular disease in humans (exposure to BPA, ΣDEHP, or PrP) (20.8% for BPA, 39.6% for ΣDEHP, 14.1% for PrP).
“In lipid mediation analyses, the estimated HDL-C-related mediation proportions were 20.8% for BPA, 39.6% for ΣDEHP, and 14.1% for PrP”
Humansexposure to BPA, ΣDEHP, or PrPn = 3,831
Environmental research
HDL-C is linked with cardiovascular disease in humans (total effects of PM2.5, BC, SO42−, and OM on CVD) (10.46% to 39.35% mediated).
“high-density lipoprotein-cholesterol (HDL-C) played a mediating role in the total effects, accounting for 10.46%, 24.96%, 39.35%, and 24.74% of PM2.5, BC, SO42−, and OM, respectively”
Humanstotal effects of PM2.5, BC, SO42−, and OM on CVDn = 21,102
Nutrition, metabolism, and cardiovascular diseases : NMCD
Cognitive function
upin humans1no changein humans1
2 studies
Cognitive function
upin humans1no changein humans1
HDL-C is linked with better cognitive function in humans (β = 0.45, 95% CI 0.29-0.62, p < 0.001).
“In fully adjusted linear models, men showed consistently positive associations across all cognitive domains, including delayed recall (β = 0.10, 95% CI 0.04-0.17, p < 0.001), immediate recall (β = 0.06, 95% CI 0.00-0.12, p = 0.047), verbal fluency (β = 0.20, 95% CI 0.14-0.26, p < 0.001), processing speed (β = 0.09, 95% CI 0.05-0.14, p < 0.001), and overall composite score (β = 0.45, 95% CI 0.29-0.62, p < 0.001).”
Humansmalesn = 2,777
BioData mining
HDL-C was not clearly linked with cognitive function in humans (β = -0.008; P > 0.05).
“higher baseline HDL-C levels did not significantly predict cognitive performance or depression 4 years later”
Humans4 yearsn = 4,302
Lipids in health and disease
Subclinical carotid atherosclerosis
downin humans1
1 study
Subclinical carotid atherosclerosis
downin humans1
HDL-C is linked with less subclinical carotid atherosclerosis in prediabetic subgroup.
“factors independently associated with SCAS included age, sex, 2 h postprandial glucose, total cholesterol, and HDL-C (protective)”
Humansin prediabetic subgroup
Frontiers in cardiovascular medicine
Depression
mediatesin humans1
1 study
Depression
mediatesin humans1
HDL-C is linked with depression in humans (mediation of the GDF15 association with depression) (7.51% of the association with depression).
“High-density lipoprotein cholesterol (HDL-C) accounted for an estimated 7.51% of the association with depression”
Humansmediation of the GDF15 association with depression
Peripheral GDF15 as an early biomarker for brain disorders: A large prospective cohort study
Progress in neuro-psychopharmacology & biological psychiatry
Diabetes mellitus
mediatesin humans1
1 study
Diabetes mellitus
mediatesin humans1
HDL-C is linked with diabetes mellitus in humans (prediabetes) (14.47% of overall effect).
“high-density lipoprotein (HDL), triglycerides (TG), and C-reactive protein (CRP) partially mediated the effect between RMS and prediabetes progression, accounting for 14.47%, 4.41%, and 0.21% of the overall effect”
Humansprediabetesn = 3,250
Diabetes & metabolic syndrome
Mortality
mediatesin humans1
1 study
Mortality
mediatesin humans1
HDL-C is linked with mortality in humans (low BMI and mortality in type 2 diabetes mellitus) (PE = –111.99%, βACME = 1.44, 95% CI: 1.33 ~ 1.56).
“Mediation analysis demonstrated significant negative mediation for TC (proportion mediated, PE = –16.68%), HDL-C (PE = –111.99%), and LDL-C (PE = –4.12%), with HDL-C showing the strongest masking effect”
Humanslow BMI and mortality in type 2 diabetes mellitusn = 372,559
Diabetology & metabolic syndrome
PhenoAge
downin humans1
1 study
PhenoAge
downin humans1
HDL-C is linked with lower PhenoAge in humans (1.60 < HDL-C ≤ 3.90 mmol/L combined with abdominal SFA ≤ 3.137 m2 or VFA ≤ 0.925 m2).
“whereas 1.60 < HDL-C ≤ 3.90 mmol/L combined with abdominal SFA ≤ 3.137 m2 or VFA ≤ 0.925 m2 decelerated PhenoAge.”
Humans1.60 < HDL-C ≤ 3.90 mmol/L combined with abdominal SFA ≤ 3.137 m2 or VFA ≤ 0.925 m2
Lipids in health and disease
PhenoAgeAccel
mediatesin humans1
1 study
PhenoAgeAccel
mediatesin humans1
HDL-C is linked with PhenoAgeAccel in humans (21.7% mediated).
“accounting for 21.7% of the relationship between VFA and PhenoAgeAccel”
Humans
Lipids in health and disease
Depressive symptoms
no changein humans1
1 study
Depressive symptoms
no changein humans1
HDL-C was not clearly linked with depressive symptoms in humans (β = 0.023; P > 0.05).
“higher baseline HDL-C levels did not significantly predict cognitive performance or depression 4 years later”
Humans4 yearsn = 4,302
Lipids in health and disease
Stroke
no changein humans1OR 1.29
1 study
Stroke
no changein humans1OR 1.29
HDL-C was not clearly linked with stroke in humans (HDL-C > 1.55 mmol/L) (OR 1.29, 95% CI 0.79-2.09).
“above 1.55 mmol/L, the incidence of stroke was not significant (OR = 1.29, 95% CI: 0.79-2.09, p>.05).”
HumansHDL-C > 1.55 mmol/L
The association between HDL-C and stroke in the middle-aged and elderly: A cross-sectional study
Brain and behavior
Upstream
2APOE ε4 allele
downin humans1
1 study
APOE ε4 allele
downin humans1
APOE ε4 allele is linked with lower HDL-C in humans (carriers versus noncarriers).
“the ε4 carriers were lower than noncarriers in middle-aged males (P < 0.05)”
Humanscarriers versus noncarriersmales
Lipids in health and disease
APOE ε2 allele
upin humans1
1 study
APOE ε2 allele
upin humans1
APOE ε2 allele is linked with higher HDL-C in humans (carriers versus noncarriers).
“the ε2 carriers were higher than the noncarriers in middle-aged females (all P < 0.05)”
Humanscarriers versus noncarriersfemales
Lipids in health and disease
Associations
70Mortality
upin humans3downin humans1HR 0.977–4.33
3 studies
Mortality
upin humans3downin humans1HR 0.977–4.33
HDL-C is associated with mortality in humans (Extremely low HDL-C (<20 mg/dL) compared with markedly low HDL-C (20–29 mg/dL)) (29.4% vs. 11.6%; HR 4.33, 95% CI 1.58–11.91).
“all-cause mortality was higher in the extremely low HDL-C group (29.4% vs. 11.6%; hazard ratio, 4.33; 95% CI, 1.58–11.91; p = 0.004)”
HumansExtremely low HDL-C (<20 mg/dL) compared with markedly low HDL-C (20–29 mg/dL)median 2.57 years68.9% malesn = 164
Annals of medicine
HDL-C predicts mortality in humans (hospitalized) (AUC 0.67 (95% CI 0.60-0.74)).
“the area under the curve value was 0.67 (95% CI 0.60-0.74) and the cut-off value of HDL-C was 31 mg/dL.”
Humanshospitalized30 daysn = 493
Cureus
HDL-C is linked with a lower risk of mortality in humans (hospitalized) (HR 0.977, 95% CI 0.955-0.998).
“In a multivariate model, the HDL-C showed a hazard ratio of 0.977 (95% confidence interval (CI) 0.955-0.998).”
Humanshospitalized30 daysn = 493
Cureus
HDL-C is linked with a higher risk of mortality in humans (HR: 1.10, 95% CI: 1.05,1.16).
“The risk of all-cause and CVD mortality in participants in the fourth quartile group compared with those in the second HDL-C quartile group was (HR: 1.10, 95% CI: 1.05,1.16)”
Humansn = 69,068
Frontiers in endocrinology
Alzheimer's disease
upin humans2downin silico1OR 0.51–3
3 studies
Alzheimer's disease
upin humans2downin silico1OR 0.51–3
HDL-C is associated with Alzheimer's disease in humans (OR 1.09, 95% CI 1.00-1.19).
“Genetically predicted high-density lipoprotein cholesterol (HDL-C) showed only a nominal association with Alzheimer disease (odds ratio 1.09, 95% confidence interval 1.00-1.19; P = 0.0459)”
Humans
Diabetes & metabolic syndrome
HDL-C is associated with Alzheimer's disease in humans (lower longitudinal trajectories) (OR = 3.0, 95% CI = 1.6-5.7).
“Lower HDL-C trajectories (OR = 3.0, 95% CI = 1.6-5.7) and the lowest VIM quintile of total cholesterol (OR = 2.4, 95% CI = 1.5-3.9) were associated with higher AD risk.”
Humanslower longitudinal trajectoriesblooddecade prior to first cognitive symptoms
Lipid Trajectories Improve Risk Models for Alzheimer's Disease and Mild Cognitive Impairment
medRxiv : the preprint server for health sciencesPreprint
HDL-C lowers the risk of Alzheimer's disease in silico (OR = 0.51, 95% CI 0.29-0.89, p = 0.019).
“MR analyses indicated a protective association between genetically predicted HDL-C and Alzheimer's disease risk (OR = 0.51, 95% CI 0.29-0.89, p = 0.019).”
In silico
BioData mining
Sleep duration
downin humans2
2 studies
Sleep duration
downin humans2
Sleep duration is associated with HDL-C in humans with insomnia symptoms (p < 0.05).
“participants who slept longer (>8 h/day) or shorter (<6 h/day) periods of time with insomnia symptoms had significantly increased ORs of low HDL-C in all models (p < 0.05)”
Humanswith insomnia symptoms
International journal of environmental research and public health
HDL-C is associated with sleep duration in humans (β2 = -0.006, P = 0.002).
“HDL-cholesterol was negatively associated with sleep duration 4 year later (β2 = -0.006, P = 0.002).”
Humans4 yearn = 5,016
Frontiers in public health
Sleep duration is associated with HDL-C in humans (β1 = -0.171, P = 0.005).
“Sleep duration was negatively associated with HDL-cholesterol 4 year later (β1 = -0.171, P = 0.005)”
Humans4 yearn = 5,016
Frontiers in public health
Cardiovascular mortality
upin humans2HR 1.52–1.583
2 studies
Cardiovascular mortality
upin humans2HR 1.52–1.583
HDL-C is linked with a higher risk of cardiovascular mortality in humans (adjusted HR: 1.52; 95% CI 1.04-2.24).
“Multivariable analysis revealed that very high HDL-C was associated with increased cardiovascular mortality (adjusted HR: 1.52; 95% CI 1.04-2.24; p = 0.03).”
Humans5.9 years
Association between very high HDL-C levels and cardiovascular mortality
European journal of medical research
HDL-C is associated with cardiovascular mortality in humans (HDL-C concentration of 20 mg/dL) (HR 1.583 at HDL-C 20 mg/dL).
“At the extremes, HR reached 1.583 at 20 mg/dL (low HDL risk)”
ReviewHDL-C concentration of 20 mg/dL
AHA Scientific Sessions 2026 abstract
Cognitive function
mixedin humans1upin humans1
2 studies
Cognitive function
mixedin humans1upin humans1
HDL-C is associated with cognitive function in humans (inverted U-shaped relationship).
“Further concentration-response analyses revealed a linear positive association in men and an inverted U-shaped relationship in women.”
Humansfemalesn = 2,777
BioData mining
HDL-C is associated with cognitive function in humans (dementia-free older adults) (B = 0.130, 95% CI: 0.001-0.261, p = 0.049).
“and global cognition (B = 0.130, 95% CI: 0.001-0.261, p = 0.049).”
Humansdementia-free older adultsn = 196
Nutrients
Cognitive impairment
upin humans2OR 1.02
2 studies
Cognitive impairment
upin humans2OR 1.02
Cognitive impairment is associated with HDL-C in humans (β = -0.036 for baseline cognition; P < 0.05).
“The analysis revealed unidirectional effects of baseline impaired cognition and greater severity of depression on increased HDL-C levels at follow-up”
Humans4 yearsn = 4,302
Lipids in health and disease
HDL-C is associated with cognitive impairment in humans (primary care) (OR=1.02, 95% CI 1.01-1.04, P=0.011).
“Logistic regression showed that HDL-c (OR=1.02 [IC=95%; 1.01-1.04]; P=0.011), and age (OR=1.05 [IC=95%; 1.02-1.08]; P=0.004) are independent factors associated with CI.”
Humansprimary caren = 424
Current Alzheimer research
Age
upin humans2
2 studies
Age
upin humans2
HDL-C is associated with age in humans (longevity group only) (r = 0.213, p < 0.001).
“Scatter plot showed a moderately strong linear relationship between the HDL-C level and age in longevity group (r = 0.213, p < 0.001).”
Humanslongevity group only
Aging
Age is associated with HDL-C in humans.
“and HDL-C increased”
Humans
Scientific reports
Cancer
upin humans1+29%
1 study
Cancer
upin humans1+29%
HDL-C is associated with cancer in humans (Extremely low HDL-C (<20 mg/dL); active malignancy) (29.4%).
“Extremely low HDL-C was more frequently associated with liver disease (41.2%) and active malignancy (29.4%)”
HumansExtremely low HDL-C (<20 mg/dL); active malignancy
Annals of medicine
Liver disease
upin humans1+41%
1 study
Liver disease
upin humans1+41%
HDL-C is associated with liver disease in humans (Extremely low HDL-C (<20 mg/dL)) (41.2%).
“Extremely low HDL-C was more frequently associated with liver disease (41.2%) and active malignancy (29.4%)”
HumansExtremely low HDL-C (<20 mg/dL)
Annals of medicine
Perceived caregiving difficulty
downin humans1
1 study
Perceived caregiving difficulty
downin humans1
Perceived caregiving difficulty is associated with HDL-C in humans (Indirect B = -.025, 95% CI: -.059, -.001).
“of caregiving difficulty on HDL-C through self-care adherence (B = -.025, 95% CI: -.059, -.001)”
HumansRural caregivers of patients with chronic illness; indirect association through self-care adherence77.7% femalesn = 283
AHA Scientific Sessions 2026 abstract
APOB
downin humans1
1 study
APOB
downin humans1
APOB is associated with HDL-C in hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months (β = -0.121, P = .004).
“lower posttreatment HDL-C (β = -0.121; P = .004)”
Human trialin hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months3 monthsn = 79
Journal of cardiovascular pharmacology and therapeutics
Patient-reported physical health
downin humans1
1 study
Patient-reported physical health
downin humans1
Patient-reported physical health is associated with HDL-C in humans across all participants following lifestyle interventions (ρ=-0.50, adjusted p = 1.00).
“Improvements in patient-reported physical health were associated with reductions in HDL-c, ApoA1 concentrations, and medium HDLp”
Human trialacross all participants following lifestyle interventionsn = 20
BMC rheumatology
Cholesterol efflux capacity
upin humans1
1 study
Cholesterol efflux capacity
upin humans1
Cholesterol efflux capacity is associated with HDL-C in dyslipidemia, CoQ10 group (r, 0.30).
“A positive correlation was found between the changes in CEC and HDL cholesterol in the CoQ10 group (r, 0.30; P = 0.032).”
Human trialin dyslipidemia, CoQ10 group120 mg/d24 wkn = 51
Nutrition (Burbank, Los Angeles County, Calif.)
Low-intensity aerobic training
upin humans1
1 study
Low-intensity aerobic training
upin humans1
Low-intensity aerobic training is associated with HDL-C in humans (healthy) (r = .75, P < .01).
“In addition, the total weekly exercise duration also showed a significant positive relationship with HDL-C (r = .75, P < .01), HDL2-C (r = .81, P < .01)”
Human trialhealthy5 monthsn = 20
Metabolism: clinical and experimental
All 70Fewer
How this record changed
Summary rewritten as its findings changed.
As it read before
Higher HDL-C is associated with lower coronary disease risk but higher fracture and mortality risks in human studies; cognitive associations point both ways, including an inverted-U relationship in women. Human trials report HDL-C increases with obicetrapib and walking in women; time-restricted feeding shows an increase in women but no overall change.
Summary rewritten as its findings changed.
As it read before
Human studies report differing associations for HDL-C: one reports protection against subclinical carotid atherosclerosis in prediabetes, another links it to Alzheimer’s disease, and another reports increased colorectal adenomatous polyp recurrence after polypectomy. A human preprint links air pollution to HDL-C.
Summary written from the findings.